FOLFIRINOX, a multi-drug chemotherapy combination, significantly improves overall survival in metastatic pancreatic cancer compared to gemcitabine alone, with median overall survival of 11.1 months versus 6.8 months respectively. Another common regimen combines nab-paclitaxel with gemcitabine, which has also been shown to improve survival compared to gemcitabine monotherapy, with a median overall survival of 8.5 months versus 6.7 months.